[Factors Contributing to the Occurrence of Edema in Breast Cancer Patients Receiving DTX Treatment].

Edema is a frequent side effect observed in patients receiving docetaxel hydrate(DTX)treatment. However, the factors contributing to the development of edema in breast cancer patients receiving this treatment have not been completely elucidated. In this study, we examined the electronic medical records of breast cancer patients who received 4 courses of DTX ± trastuzumab therapy at the Hokkaido Cancer Center between January 2017 and February 2018 to investigate the occurrence of edema and related factors. We found that edema was confirmed in 23(42.6%)of the 54 surveyed patients. Further, HER2- positive and high BNP levels before the start of treatment were shown to be factors related to edema development. In particular, the results suggested that when DTX is administered in combination with trastuzumab, it is necessary to monitor early and frequently the occurrence of edema.